Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)

September 19, 2024 UCBN News, Syndication Comments Off on Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)

BOULDER, Colo.–(BUSINESS WIRE)–Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced top-line data of EDG-7500 from the Phase 1 trial in healthy subjects and the single-dose arm of the Phase 2 CIRRUS-HCM trial in patients with obstructive HCM. EDG-7500 is a novel oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with HCM. In the pla
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

Related Articles

News

Neurexis Therapeutics Secures $3 Million NIH Grant to Advance Neuroprotective Treatment for Global Cerebral Ischemia

September 18, 2024 UCBN News, Syndication Comments Off on Neurexis Therapeutics Secures $3 Million NIH Grant to Advance Neuroprotective Treatment for Global Cerebral Ischemia

A promising approach for preventing cognitive and behavioral impairment following ischemia AURORA, Colo., Sept. 18, 2024 /PRNewswire-PRWeb/ — Neurexis Therapeutics, a leading biopharmaceutical company focused on developing neuroprotective interventions, has been awarded a prestigious $3… […]